Oral Health in Africa: Promoting Collaborative Solutions

By Crystal Lubbe

April 1, 2025

Is oral health taking a back seat in public health discussions in Africa? This article brings to the forefront the pressing challenges confronting oral health across the continent. Specifically, it highlights the widespread prevalence of untreated dental diseases and the critical shortage of oral health professionals—with the number of dentists ranging from just 1.77 to as few as 0.03 per 10,000 people. Consequently, millions continue to suffer from a high burden of untreated oral conditions, including dental caries, periodontal disease, oral cancers, HIV-related complications, and noma, all of which severely compromise quality of life.

Key Insights:

  • Oral Disease Burden: Untreated dental caries and periodontal disease are widespread in Africa. Regional variations are influenced by socioeconomic and dietary factors.
  • Workforce and Policy Gaps: Many countries face a critical shortage of dentists and dental care assistants. Inadequate oral health policies worsen the problem.
  • Collaborative Solutions: Partnerships among healthcare providers, industry, civil society, and academia are key to improving oral health outcomes.
  • Prevalence of Oral disease: Untreated caries (5+ years) is highest in Northern Africa (33.72%), severe periodontal disease (15+ years) in Western Africa (26.75%), and new lip and oral cavity cancer cases in Northern Africa (median: 269.5 cases). See Table 1 for details.
Table 1: Burden of major oral diseases in Africa (Foláyan et al 2015)

Background Context:

WHO reports Africa has seen the largest global rise in oral diseases over 30 years. Nearly 44% of the population is affected. Only 57% of African countries have a national oral health policy. The region spends less than US$1 per person annually on oral health. WHO’s Global Oral Health Strategy aims for universal coverage by 2030, focusing on prevention and community-based interventions.

Implications:

  • Health Economics: Oral diseases cause significant economic losses due to healthcare costs and lost productivity. Prevention and better care access can bring long-term benefits.
  • Health Outcomes: Integrating oral health into primary healthcare and community interventions can improve overall well-being.
  • Policy and Research: Strengthening local research is vital for evidence-based policies.

To address these issues effectively, stakeholders must take coordinated action. In particular, integrating oral health into national public health policies remains essential for expanding access to care. Furthermore, national dental associations, working in partnership with public health institutions and international organisations, can drive meaningful policy change and promote better resource allocation. Through such collaborative efforts, Africa can begin to close the oral health gap and deliver improved outcomes for its population. For more details, see the original article.

 

Reference url

Recent Posts

PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment

By João L. Carapinha

May 19, 2026

New data from the PSMAddition study indicate that Pluvicto combined with standard of care, consisting of an androgen receptor pathway inhibitor plus androgen deprivation therapy, produced a 58% lower risk of prostate-specific antigen progression compared with standard of care alone. Patients rece...
Financing Boosts Vaccine Manufacturing Africa: New Facility to Enhance Local Production Capacity

By João L. Carapinha

In a major step forward for vaccine manufacturing Africa, Biovac has secured a financing package from the International Finance Corporation (IFC), the EIB Group, and the European Commission to build the continent’s first end-to-end multi-vaccine production facility. Landmark Funding ...
Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvant Settings

By João L. Carapinha

May 18, 2026

Enhertu breast cancer treatment has secured FDA approval for neoadjuvant use in adults with HER2-positive Stage II or III disease before surgery, followed by taxane plus trastuzumab and pertuzumab, and for adjuvant therapy in patients with residual invasive disease after prior trastuzumab-based r...